WO1990003400A1 - Intercellular adhesion molecules, and their binding ligands - Google Patents

Intercellular adhesion molecules, and their binding ligands Download PDF

Info

Publication number
WO1990003400A1
WO1990003400A1 PCT/US1989/004242 US8904242W WO9003400A1 WO 1990003400 A1 WO1990003400 A1 WO 1990003400A1 US 8904242 W US8904242 W US 8904242W WO 9003400 A1 WO9003400 A1 WO 9003400A1
Authority
WO
WIPO (PCT)
Prior art keywords
icam
antibody
binding
cells
lfa
Prior art date
Application number
PCT/US1989/004242
Other languages
English (en)
French (fr)
Inventor
Timothy A. Springer
Robert Rothlein
Steven D. Marlin
Michael L. Dustin
Original Assignee
Dana-Farber Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute filed Critical Dana-Farber Cancer Institute
Priority to RU92016375A priority Critical patent/RU2126449C1/ru
Priority to KR1019900701105A priority patent/KR900701846A/ko
Publication of WO1990003400A1 publication Critical patent/WO1990003400A1/en
Priority to FI902490A priority patent/FI102181B1/fi
Priority to DK199001289A priority patent/DK175362B1/da
Priority to NO902311A priority patent/NO902311D0/no
Priority to FI981097A priority patent/FI107451B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
PCT/US1989/004242 1988-09-28 1989-09-28 Intercellular adhesion molecules, and their binding ligands WO1990003400A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
RU92016375A RU2126449C1 (ru) 1988-09-28 1989-09-28 Производное вещества межклеточной адгезии icam-1, последовательность днк
KR1019900701105A KR900701846A (ko) 1988-09-28 1989-09-28 세포간 점착분자 및 이의 결합 리간드
FI902490A FI102181B1 (fi) 1988-09-28 1990-05-21 Menetelmä ICAM-1 (solujen välisen kiinnikemolekyylin) saamiseksi oleellisesti puhtaassa muodossa
DK199001289A DK175362B1 (da) 1988-09-28 1990-05-25 Oplöseligt funktionelt derivat af ICAM-1, rekombinant DNA-molekyle og fremgangsmåde til fremstilling af nævnte derivat, farmaceutisk præparat indeholdende et sådant derivat og derivatets anvendelse til fremstilling af et sådant præparat, samt....
NO902311A NO902311D0 (no) 1988-09-28 1990-05-25 Intracellulaere adhesjonsmolekyler og deres bindingsligander.
FI981097A FI107451B (fi) 1988-09-28 1998-05-18 Menetelmä ICAM-1 (solujen välisen kiinnikemolekyylin) saamiseksi oleellisesti puhtaassa muodossa

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25044688A 1988-09-28 1988-09-28
US250,446 1988-09-28
US37388289A 1989-06-30 1989-06-30
US373,882 1989-06-30

Publications (1)

Publication Number Publication Date
WO1990003400A1 true WO1990003400A1 (en) 1990-04-05

Family

ID=26940882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/004242 WO1990003400A1 (en) 1988-09-28 1989-09-28 Intercellular adhesion molecules, and their binding ligands

Country Status (7)

Country Link
JP (1) JP2976381B2 (ko)
KR (1) KR900701846A (ko)
AU (2) AU4412889A (ko)
DK (1) DK175362B1 (ko)
FI (2) FI102181B1 (ko)
HU (1) HU218904B (ko)
WO (1) WO1990003400A1 (ko)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0391088A2 (en) * 1989-03-16 1990-10-10 Center For Blood Research Laboratories, Inc. Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
WO1992000751A1 (en) * 1990-07-06 1992-01-23 Novo Nordisk A/S A pharmaceutical composition comprising a cell adhesion molecule
WO1993025218A1 (en) * 1992-06-11 1993-12-23 The Scripps Research Institute Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation
WO1994008620A1 (en) * 1992-10-09 1994-04-28 Center For Blood Research, Inc. A subpopulation of mac-1 (cd11b/cd18) molecules which mediate neutrophil adhesion to icam-1 and fibrinogen
WO1995010533A1 (de) * 1993-10-15 1995-04-20 KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG Peptide zur tumortherapie
US5589453A (en) * 1988-09-01 1996-12-31 Molecular Therapeutics, Inc. Human rhinovirus receptor protein (ICAM-1) that inhibits rhinovirus attachment and infectivity
WO1997000956A1 (en) * 1995-06-20 1997-01-09 Trustees Of Boston University Hypoxia-responsive adhesion molecules, specific antibodies, and their uses
US5599790A (en) * 1992-06-11 1997-02-04 The Scripps Research Institute Fibrinogen γ chain polypeptide and compositions thereof
EP0762886A1 (en) * 1994-04-19 1997-03-19 The University Of Kansas Icam-1/lfa-1 short-chain peptides and method of using same
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
WO2001015733A2 (en) * 1999-09-01 2001-03-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compositions for treating autoimmune disease containing a compounds which regulates icam-lfa-1 interaction and a compounds which regulates cd40-cd40 ligand interaction
US6844011B1 (en) 1990-08-30 2005-01-18 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US7314938B2 (en) 2003-11-05 2008-01-01 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8084047B2 (en) 2005-05-17 2011-12-27 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9085553B2 (en) 2012-07-25 2015-07-21 SARcode Bioscience, Inc. LFA-1 inhibitor and methods of preparation and polymorph thereof
WO2019105864A1 (en) 2017-11-30 2019-06-06 F. Hoffmann-La Roche Ag B-cell cultivation method
US10960087B2 (en) 2007-10-19 2021-03-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018010A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof
WO1991018011A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
CA2056143A1 (en) * 1990-11-28 1992-05-29 Michael S. Diamond The mac-1 binding site of icam-1
CN101918452A (zh) * 2007-11-15 2010-12-15 中外制药株式会社 与Anexelekto结合的单克隆抗体及其利用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289949A2 (en) * 1987-05-04 1988-11-09 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2064327T3 (es) * 1987-11-02 1995-02-01 Baylor College Medicine Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289949A2 (en) * 1987-05-04 1988-11-09 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CELL, Vol. 51(5), 1987, MARLIN, "Purified Intercellular Adhesion Molecule-1 (ICAM-1) is a Ligand for Lymphocyte Function-Associated Antigen 1 (LFA-1)", pages 813-820. *
JOURNAL OF IMMUNOLOGY, Vol. 137(1), 1986, DUSTIN, "Induction by Interleukin-1 and Interferon-Gamma Tissue Distribution Biochemistry and Function of a Natural Adherence Molecule Intracellular Adherence Molecule-1", pages 245-254. *
JOURNAL OF IMMUNOLOGY, Vol. 137(4), 1986, ROTHLEIN, "A Human Intercellular Adhesion Molecule (ICAM-1) Distinct from LFA-1 - Isolation and Characterization", pages 1270-1274. *

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589453A (en) * 1988-09-01 1996-12-31 Molecular Therapeutics, Inc. Human rhinovirus receptor protein (ICAM-1) that inhibits rhinovirus attachment and infectivity
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
EP0391088A2 (en) * 1989-03-16 1990-10-10 Center For Blood Research Laboratories, Inc. Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
EP0391088A3 (en) * 1989-03-16 1991-10-02 Center For Blood Research Laboratories, Inc. Use of functional derivatives of the intercellular adhesion molecule icam-1 in anti-viral therapy
WO1992000751A1 (en) * 1990-07-06 1992-01-23 Novo Nordisk A/S A pharmaceutical composition comprising a cell adhesion molecule
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6844011B1 (en) 1990-08-30 2005-01-18 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US7176184B2 (en) 1992-02-12 2007-02-13 Biogen Idec Ma Inc. Treatment for inflammatory bowel disease with a fibronectin polypeptide
US6265549B1 (en) 1992-06-11 2001-07-24 The Scripps Research Institute Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation
US6737058B2 (en) 1992-06-11 2004-05-18 The Scripps Research Institute Methods for inhibiting endothelial cell and fibrinogen mediated inflammation using fibrinogen specific antibodies
US5919754A (en) * 1992-06-11 1999-07-06 The Scripps Research Institute Method of inhibiting fibrinogen binding to endothelial cells with fibrinogen gamma chain peptides
WO1993025218A1 (en) * 1992-06-11 1993-12-23 The Scripps Research Institute Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation
US5599790A (en) * 1992-06-11 1997-02-04 The Scripps Research Institute Fibrinogen γ chain polypeptide and compositions thereof
US6676940B2 (en) 1992-06-11 2004-01-13 The Scripps Research Institute Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation
WO1994008620A1 (en) * 1992-10-09 1994-04-28 Center For Blood Research, Inc. A subpopulation of mac-1 (cd11b/cd18) molecules which mediate neutrophil adhesion to icam-1 and fibrinogen
DE4335273A1 (de) * 1993-10-15 1995-04-20 Univ Ludwigs Albert Peptide zur Tumortherapie
WO1995010533A1 (de) * 1993-10-15 1995-04-20 KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG Peptide zur tumortherapie
EP0762886A4 (en) * 1994-04-19 1999-03-31 Univ Kansas ICAM-1 / LFA-1 SHORT CHAIN PEPTIDES AND METHODS FOR USE THEREOF
EP0762886A1 (en) * 1994-04-19 1997-03-19 The University Of Kansas Icam-1/lfa-1 short-chain peptides and method of using same
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US6482409B1 (en) 1994-08-11 2002-11-19 Biogen, Inc. Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein
WO1997000956A1 (en) * 1995-06-20 1997-01-09 Trustees Of Boston University Hypoxia-responsive adhesion molecules, specific antibodies, and their uses
WO2001015733A3 (en) * 1999-09-01 2001-09-13 Boehringer Ingelheim Pharma Compositions for treating autoimmune disease containing a compounds which regulates icam-lfa-1 interaction and a compounds which regulates cd40-cd40 ligand interaction
WO2001015733A2 (en) * 1999-09-01 2001-03-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compositions for treating autoimmune disease containing a compounds which regulates icam-lfa-1 interaction and a compounds which regulates cd40-cd40 ligand interaction
US7314938B2 (en) 2003-11-05 2008-01-01 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US7745460B2 (en) 2003-11-05 2010-06-29 Sarcode Corporation Modulators of cellular adhesion
US7790743B2 (en) 2003-11-05 2010-09-07 Sarcode Corporation Modulators of cellular adhesion
US7928122B2 (en) 2003-11-05 2011-04-19 Sarcode Corporation Modulators of cellular adhesion
US7989626B2 (en) 2003-11-05 2011-08-02 SAR code Corporation Modulators of cellular adhesion
US8071617B2 (en) 2003-11-05 2011-12-06 Sarcode Bioscience Inc. Modulators of cellular adhesion
US9248126B2 (en) 2003-11-05 2016-02-02 Sarcode Bioscience Inc. Modulators of cellular adhesion
US9216174B2 (en) 2003-11-05 2015-12-22 Sarcode Bioscience Inc. Modulators of cellular adhesion
US9045457B2 (en) 2005-05-17 2015-06-02 Sarcode Bioscience Inc. Compositions and methods for treatment
US8168655B2 (en) 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US8084047B2 (en) 2005-05-17 2011-12-27 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US8592450B2 (en) 2005-05-17 2013-11-26 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US8758776B2 (en) 2005-05-17 2014-06-24 Sarcode Bioscience Inc. Compositions and methods for treatment
US8771715B2 (en) 2005-05-17 2014-07-08 Sarcode Bioscience Inc. Compositions and methods for treatment
US9051297B2 (en) 2005-05-17 2015-06-09 Sarcode Bioscience Inc. Compositions and methods for treatment
US9045458B2 (en) 2005-05-17 2015-06-02 Sarcode Bioscience Inc. Compositions and methods for treatment
US10188641B2 (en) 2005-05-17 2019-01-29 Sarcode Bioscience Inc. Compositions and methods for treatment
US10960087B2 (en) 2007-10-19 2021-03-30 Novartis Ag Compositions and methods for treatment of diabetic retinopathy
US8367701B2 (en) 2008-04-15 2013-02-05 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8871935B2 (en) 2008-04-15 2014-10-28 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US11028077B2 (en) 2008-04-15 2021-06-08 Novartis Pharmaceuticals Corporation Crystalline pharmaceutical and methods of preparation and use thereof
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8927574B2 (en) 2009-10-21 2015-01-06 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9890141B2 (en) 2009-10-21 2018-02-13 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9353088B2 (en) 2009-10-21 2016-05-31 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US10214517B2 (en) 2012-07-25 2019-02-26 Sarcode Bioscience Inc. LFA-1 inhibitor and methods of preparation and polymorph thereof
US10906892B2 (en) 2012-07-25 2021-02-02 Novartis Pharmaceuticals Corporation LFA-1 inhibitor and methods of preparation and polymorph thereof
US9085553B2 (en) 2012-07-25 2015-07-21 SARcode Bioscience, Inc. LFA-1 inhibitor and methods of preparation and polymorph thereof
WO2019105864A1 (en) 2017-11-30 2019-06-06 F. Hoffmann-La Roche Ag B-cell cultivation method
US11952586B2 (en) 2017-11-30 2024-04-09 Hoffmann-La Roche Inc. B-cell cultivation method

Also Published As

Publication number Publication date
AU6319294A (en) 1994-08-25
AU679506B2 (en) 1997-07-03
JP2976381B2 (ja) 1999-11-10
DK128990D0 (da) 1990-05-25
HU218904B (hu) 2000-12-28
HU896074D0 (en) 1990-11-28
HUT56120A (en) 1991-07-29
DK175362B1 (da) 2004-09-13
FI107451B (fi) 2001-08-15
DK128990A (da) 1990-07-26
JPH03501861A (ja) 1991-04-25
FI981097A (fi) 1998-05-18
AU4412889A (en) 1990-04-18
FI981097A0 (fi) 1989-09-28
KR900701846A (ko) 1990-12-04
FI902490A0 (fi) 1990-05-21
FI102181B (fi) 1998-10-30
FI102181B1 (fi) 1998-10-30

Similar Documents

Publication Publication Date Title
EP0289949B1 (en) Intercellular adhesion molecules, and their binding ligands
AU679506B2 (en) Intercellular adhesion molecules, and their binding ligands
US5475091A (en) R6-5-D6, an antibody which binds intercellular adhesion molecule-1
EP0606518B1 (en) Intercellular adhesion molecules and their binding ligands
RU2130782C1 (ru) Рекомбинантная молекула днк, кодирующая молекулу iсам-3, молекула адгезии iсам-3, антитело, способное связываться с такой молекулой, фармацевтическая композиция
US5831036A (en) Soluble fragments of human intercellular adhesion molecule-1
US5891841A (en) Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
AU629189B2 (en) Intercellular adhesion molecules and their binding ligands
JP3778922B2 (ja) 細胞間粘着分子およびその結合性リガンド
US20090035321A1 (en) Intercellular adhesion molecules and their binding ligands
DK176020B1 (da) Monoklonale antistoffer og fragmenter deraf, hybridomaceller til fremstilling af monoklonale antistoffer, fremgangsmåder til diagnosticering af tumorceller, anvendelse af antistoffer samt farmaceutiske præparater indeholdende samme
IE19960275A1 (en) Intercellular adhesion molecules, and their binding ligands
NZ244853A (en) Antibodies and fragments to icam-1, pharmaceutical composition
IE83840B1 (en) Intercellular adhesion molecules, and their binding ligands

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI HU JP KR NO SU

COP Corrected version of pamphlet

Free format text: PAGES 1/25-25/25,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER

WWE Wipo information: entry into national phase

Ref document number: 902490

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 981097

Country of ref document: FI

WWG Wipo information: grant in national office

Ref document number: 902490

Country of ref document: FI

WWG Wipo information: grant in national office

Ref document number: 981097

Country of ref document: FI